Literature DB >> 17965080

Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease.

R D Cohen1, W R Bowie, R Enns, J Flint, J M Fitzgerald.   

Abstract

The use of anti-tumour necrosis factor (TNF) agents has expanded significantly over the past few years, particularly for rheumatological diseases and Crohn's disease. A number of associated opportunistic infections have been observed as a result of suppression of T cell-mediated immunity, the most frequent being tuberculosis. We report the first case of pulmonary actinomycosis in a patient receiving regular infusions of infliximab, an anti-TNF agent, for Crohn's disease.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17965080      PMCID： PMC2117133          DOI： 10.1136/thx.2006.075150

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


  11 in total

Review 1.  Review article: the clinical role of anti-TNFalpha antibody treatment in Crohn's disease.

Authors:  S J Bell; M A Kamm
Journal:  Aliment Pharmacol Ther       Date:  2000-05       Impact factor: 8.171

2.  Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

Authors:  F J Baert; G R D'Haens; M Peeters; M I Hiele; T F Schaible; D Shealy; K Geboes; P J Rutgeerts
Journal:  Gastroenterology       Date:  1999-01       Impact factor: 22.682

Review 3.  Infections associated with tumor necrosis factor-alpha antagonists.

Authors:  Nancy F Crum; Edith R Lederman; Mark R Wallace
Journal:  Medicine (Baltimore)       Date:  2005-09       Impact factor: 1.889

4.  "Miliary" actinomycosis.

Authors:  M S Fisher
Journal:  J Can Assoc Radiol       Date:  1980-06

Review 5.  Complications of biological therapy for inflammatory bowel diseases.

Authors:  Wojciech Blonski; Gary R Lichtenstein
Journal:  Curr Opin Gastroenterol       Date:  2006-01       Impact factor: 3.287

6.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.

Authors:  Kristian Reich; Frank O Nestle; Kim Papp; Jean-Paul Ortonne; Robert Evans; Cynthia Guzzo; Shu Li; Lisa T Dooley; Christopher E M Griffiths
Journal:  Lancet       Date:  2005 Oct 15-21       Impact factor: 79.321

Review 7.  Actinomycoses and Nocardia pulmonary infections.

Authors:  Orhan Yildiz; Mehmet Doganay
Journal:  Curr Opin Pulm Med       Date:  2006-05       Impact factor: 3.155

8.  Pulmonary actinomycosis. A cause of endobronchial disease in a patient with AIDS.

Authors:  I Cendan; A Klapholz; W Talavera
Journal:  Chest       Date:  1993-06       Impact factor: 9.410

9.  Lung, pleural and colon actinomycosis in an immunocompromised patient: a rare form of presentation.

Authors:  K Charalabopoulos; A K Charalabopoulos; V Papalimneou; E Ioachim; S H Constantopoulos
Journal:  Chemotherapy       Date:  2003-07       Impact factor: 2.544

10.  Endobronchial actinomycosis simulating bronchogenic carcinoma. Diagnosis by bronchial biopsy.

Authors:  I Ariel; R Breuer; N S Kamal; I Ben-Dov; P Mogel; E Rosenmann
Journal:  Chest       Date:  1991-02       Impact factor: 9.410
View more
  14 in total

Review 1.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

2.  Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitis.

Authors:  Gulbu Uzel; Jordan S Orange; Nina Poliak; Beatriz E Marciano; Theo Heller; Steven M Holland
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

Review 3.  Actinomyces and related organisms in human infections.

Authors:  Eija Könönen; William G Wade
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 4.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

5.  Bronchopulmonary actinomycosis associated with hiatal hernia.

Authors:  Alessandro Andreani; Alberto Cavazza; Alessandro Marchioni; Luca Richeldi; Massimiliano Paci; Giulio Rossi
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

6.  Pulmonary actinomycosis and Hodgkin's disease: when FDG-PET may be misleading.

Authors:  C Weisshaupt; F Hitz; W C Albrich; A Omlin
Journal:  BMJ Case Rep       Date:  2014-09-22

7.  Serious events with infliximab in patients with inflammatory bowel disease: a 9-year cohort study in the Netherlands.

Authors:  Hilbert S de Vries; Martijn G H van Oijen; Dirk J de Jong
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

8.  Infliximab in the treatment of plaque type psoriasis.

Authors:  Rosita Saraceno; Andrea Saggini; Lucia Pietroleonardo; Sergio Chimenti
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-03

Review 9.  Actinomycosis: etiology, clinical features, diagnosis, treatment, and management.

Authors:  Florent Valour; Agathe Sénéchal; Céline Dupieux; Judith Karsenty; Sébastien Lustig; Pierre Breton; Arnaud Gleizal; Loïc Boussel; Frédéric Laurent; Evelyne Braun; Christian Chidiac; Florence Ader; Tristan Ferry
Journal:  Infect Drug Resist       Date:  2014-07-05       Impact factor: 4.003

10.  An overview of thoracic actinomycosis: CT features.

Authors:  Ji-Yeon Han; Ki-Nam Lee; Jae Kyo Lee; Yun Hyeon Kim; Seok Jin Choi; Yeon Ju Jeong; Mee-Sook Roh; Pil Jo Choi
Journal:  Insights Imaging       Date:  2012-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.